Pedro Rocha

1.1k total citations
33 papers, 444 citations indexed

About

Pedro Rocha is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Pedro Rocha has authored 33 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Pedro Rocha's work include Lung Cancer Research Studies (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Peptidase Inhibition and Analysis (8 papers). Pedro Rocha is often cited by papers focused on Lung Cancer Research Studies (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Peptidase Inhibition and Analysis (8 papers). Pedro Rocha collaborates with scholars based in Spain, United States and United Kingdom. Pedro Rocha's co-authors include Edurne Arriola, Álvaro Taus, Joan Albanell, Sergi Clavé, Marta Salido, Lara Pijuán, Pedro Adragão, Miguel Mendes, João Primo and João de Sousa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Pedro Rocha

28 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pedro Rocha Spain 11 260 173 105 71 70 33 444
Stavros N Georgiannos United Kingdom 10 184 0.7× 150 0.9× 70 0.7× 33 0.5× 58 0.8× 13 427
Teresa Alonso Gordoa Spain 11 284 1.1× 180 1.0× 64 0.6× 13 0.2× 84 1.2× 40 400
F. Majois Belgium 9 224 0.9× 69 0.4× 59 0.6× 55 0.8× 56 0.8× 28 350
Sławomir Falkowski Poland 11 193 0.7× 237 1.4× 32 0.3× 49 0.7× 59 0.8× 38 355
Rambha Pandey India 10 181 0.7× 160 0.9× 105 1.0× 14 0.2× 69 1.0× 50 397
Seong Woo Hong South Korea 11 234 0.9× 126 0.7× 114 1.1× 8 0.1× 87 1.2× 28 458
Jodi Lyn Layton United States 7 90 0.3× 130 0.8× 59 0.6× 25 0.4× 37 0.5× 40 350
Francisco Aparisi Spain 10 184 0.7× 167 1.0× 44 0.4× 13 0.2× 57 0.8× 30 297
Milica Kontić Serbia 11 93 0.4× 111 0.6× 44 0.4× 19 0.3× 94 1.3× 43 315
Ryo Ariyasu Japan 13 273 1.1× 266 1.5× 104 1.0× 5 0.1× 81 1.2× 51 444

Countries citing papers authored by Pedro Rocha

Since Specialization
Citations

This map shows the geographic impact of Pedro Rocha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Rocha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Rocha more than expected).

Fields of papers citing papers by Pedro Rocha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Rocha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Rocha. The network helps show where Pedro Rocha may publish in the future.

Co-authorship network of co-authors of Pedro Rocha

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Rocha. A scholar is included among the top collaborators of Pedro Rocha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Rocha. Pedro Rocha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rudin, Charles M., Melissa L. Johnson, Luis Paz‐Ares, et al.. (2025). Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. Journal of Clinical Oncology. 44(4). 261–273.
2.
Calles, Antonio, Alejandro Navarro, Maria J. de Miguel, et al.. (2025). Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study. Journal of Thoracic Oncology. 20(7). 969–982. 4 indexed citations
3.
Rocha, Pedro, Sílvia Menéndez, Ignacio Sánchez, et al.. (2025). The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. International Journal of Molecular Sciences. 26(3). 1293–1293. 2 indexed citations
4.
Rudin, Charles M., Giannis Mountzios, Byoung Chul Cho, et al.. (2025). Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.. Journal of Clinical Oncology. 43(17_suppl). 2 indexed citations
5.
Rocha, Pedro, et al.. (2024). Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases. Translational Lung Cancer Research. 13(1). 179–185. 2 indexed citations
6.
Deng, Nan, Laura Reyes-Uribe, Edwin R. Parra, et al.. (2023). Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch Syndrome colorectal mucosa. Frontiers in Immunology. 14. 1162669–1162669. 3 indexed citations
7.
Deng, Nan, Laura Reyes-Uribe, Edwin R. Parra, et al.. (2023). Naproxen Chemoprevention Induces Proliferation of Cytotoxic Lymphocytes in Lynch Syndrome Colorectal Mucosa. Zenodo (CERN European Organization for Nuclear Research).
8.
Taus, Álvaro, Pedro Rocha, Ainhoa Hernández, et al.. (2020). Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma. Archivos de Bronconeumología. 57(5). 323–329. 2 indexed citations
9.
Rocha, Pedro, Mayra Orrillo, Álvaro Taus, et al.. (2020). Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC. JTO Clinical and Research Reports. 2(1). 100115–100115. 3 indexed citations
10.
Behrens, Carmen, Pedro Rocha, Edwin R. Parra, et al.. (2020). Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer. 22(3). e415–e424. 12 indexed citations
11.
Clavé, Sergi, Lara Pijuán, Marta Lorenzo, et al.. (2019). Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns. Clinical Lung Cancer. 20(4). e421–e429. 33 indexed citations
12.
Clavé, Sergi, Beatríz Bellosillo, Marta Salido, et al.. (2019). P2.09-34 Next-Generation Sequencing Implementation in Non-Small Cell Lung Cancer Molecular Diagnosis. Journal of Thoracic Oncology. 14(10). S783–S783. 1 indexed citations
13.
Rocha, Pedro, Álvaro Taus, Maria Teresa Rodrigo‐Calvo, et al.. (2018). CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. Journal of Thoracic Oncology. 13(10). e193–e196. 24 indexed citations
14.
Rocha, Pedro & Edurne Arriola. (2018). Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. Archivos de Bronconeumología. 55(3). 124–125. 3 indexed citations
15.
Taus, Álvaro, Pedro Rocha, Lara Pijuán, et al.. (2018). Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma. Clinical Lung Cancer. 19(5). 387–394.e2. 44 indexed citations
16.
Rocha, Pedro, Oriol Arpí, Álvaro Taus, et al.. (2017). P1.15-001 Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(11). S2043–S2043. 1 indexed citations
17.
Taus, Álvaro, Ainhoa Hernández, Eva López, et al.. (2017). P1.02-039 Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients. Journal of Thoracic Oncology. 12(1). S511–S511. 1 indexed citations
18.
Casadevall, David, Sergi Clavé, Álvaro Taus, et al.. (2017). Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. Clinical Lung Cancer. 18(6). 682–691.e5. 69 indexed citations
19.
Rocha, Pedro, Charity J. Morgan, Arnoud J. Templeton, et al.. (2014). Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. Oncology Research and Treatment. 37(12). 772–776. 15 indexed citations
20.
Ghatalia, Pooja, Charity J. Morgan, Toni K. Choueiri, et al.. (2014). Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology. 94(1). 136–145. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stavros N Georgiannos Breakdown of academic impact, for papers by Teresa Alonso Gordoa Breakdown of academic impact, for papers by F. Majois Breakdown of academic impact, for papers by Sławomir Falkowski Breakdown of academic impact, for papers by Rambha Pandey Breakdown of academic impact, for papers by Seong Woo Hong Breakdown of academic impact, for papers by Jodi Lyn Layton Breakdown of academic impact, for papers by Francisco Aparisi Breakdown of academic impact, for papers by Milica Kontić Breakdown of academic impact, for papers by Ryo Ariyasu
Rankless by CCL
2026